NCT05408936View on ClinicalTrials.gov

SGLT2 Inhibitors and Effects on Hematopoiesis, Inflammation and Metabolic Markers

Active, not recruitingOBSERVATIONAL

Enrollment

80

Participants

Timeline

Start Date

June 3, 2022

Primary Completion Date

December 1, 2023

Study Completion Date

June 1, 2024

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

SGLT2 inhibitor

Patients receive an SGLT2 inhibitor as part of theirn routine care.

Trial Locations (1)

26504

University Hospital of Patras, Pátrai

All Listed Sponsors

lead

University of Patras

OTHER